FOUR DRUG REGIMEN VS THREE DRUG REGIMEN IN HIV INFECTED SUBJECTS

HIV 感染者的四种药物治疗方案与三种药物治疗方案

• 批准号: 6297258
• 负责人: Joseph J Eron
• 金额: $ 0.02万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6297258
• 关键词: 2'3' dideoxynucleoside; AIDS therapy; HIV infections; antiAIDS agent; clinical research; combination chemotherapy; drug screening /evaluation; human subject; human therapy evaluation; lamivudine; protease inhibitor; reverse transcriptase inhibitors; zidovudine

The purpose of the study is to examine whether or not the quadruple regimen of 141W94 1200 mg bid, abacavir 300 mg bid, and Combivir (TM) bid is superior in efficacy to the triple regimen of Nelfinavir 750 mg tid and Combivir (TM) bid in antiretroviral-naive, HIV-infected subjects with baseline HIV RNA > or = 5000 copies/mL and baseline CD4 > or = 50 cells/mme, in the presence of comparable safety and tolerability profiles for the treatment arms.

本研究的目的是检验 141W94 1200 mg bid、阿巴卡韦 300 mg bid 和 Combivir (TM) bid 四联方案的疗效是否优于奈非那韦 750 mg tid 和 Combivir (TM) bid 三联方案在未接受过抗逆转录病毒治疗、基线 HIV RNA > 或 = 5000 拷贝/mL 且基线 CD4 > 或 = 的 HIV 感染受试者中50 个细胞/mme，治疗组的安全性和耐受性具有可比性。